Loading company…
Nektar Therapeutics develops therapies for autoimmune, inflammatory and cancer conditions.
Nektar's research includes therapies that modulate immune responses, including Rezpegaldesleukin for patients with atopic dermatitis. It works with healthcare providers and pharmaceutical partners. The company is based in San Francisco and reported 2024 revenue of USD 98.43 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in